瑞戈非尼治疗转移性骨肉瘤患者的随机双盲II期研究
SARC024是一项II期随机双盲试验,纳入42例进展期转移性骨肉瘤患者,按1:1随机分配至瑞戈非尼或安慰剂组,疾病进展时允许交叉。瑞戈非尼组中位无进展生存期3.6个月(95%CI 2.0至7.6个月)显著优于安慰剂组1.7个月(95%CI 1.2至1.8个月),风险比0.42(95%CI 0.21至0.85,P=0.017)。研究达到主要终点,未观察到新的安全性信号。
要点
- 瑞戈非尼组中位PFS 3.6个月(95%CI 2.0至7.6个月)vs 安慰剂组1.7个月(95%CI 1.2至1.8个月),HR 0.42(95%CI 0.21至0.85,P=0.017)。
- 在交叉设计背景下,总生存期无统计学显著差异。
- 瑞戈非尼组22例中14例(64%)发生归因于治疗的3至4级事件,包括1例4级结肠穿孔。
核心结论
- 研究达到主要终点,显示瑞戈非尼在进展期转移性骨肉瘤患者中具有活性。
- 未观察到新的安全性信号。
- 瑞戈非尼应被视为复发性转移性骨肉瘤患者的一种治疗选择。
研究设计与样本
- SARC024是一项针对特定肉瘤亚型(包括晚期骨肉瘤)的多激酶抑制剂瑞戈非尼II期临床试验。
- 纳入经RECIST可测量、至少接受过一线治疗的进展期转移性骨肉瘤患者,按1:1随机分配至瑞戈非尼或安慰剂,疾病进展时允许交叉。
- 主要终点为无进展生存期(PFS),研究把握度设定为检测中位PFS至少3个月的差异。
- 2014年9月至2018年5月期间从12个中心纳入42例患者,中位年龄37岁(范围18至76岁),既往平均接受2.3线治疗方案。
- 经数据安全监查委员会审查后研究提前停止入组。
主要发现
- 瑞戈非尼组中位PFS为3.6个月(95%CI 2.0至7.6个月),安慰剂组为1.7个月(95%CI 1.2至1.8个月),风险比0.42(95%CI 0.21至0.85,P=0.017)。
- 安慰剂组有10例患者在疾病进展时交叉至活性药物。
- 在交叉设计背景下,总生存期无统计学显著差异。
- 最初随机分配至瑞戈非尼的22例患者中,14例(64%)发生归因于治疗的3至4级事件,包括1例4级结肠穿孔。
临床怎么用
- 作者认为,瑞戈非尼应被视为复发性转移性骨肉瘤患者的一种治疗选择。
局限性
- 研究提前停止入组(经数据安全监查委员会审查后)。
- 在交叉设计背景下,总生存期无统计学显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: SARC024 is a phase II clinical trial of the multikinase inhibitor regorafenib in specific sarcoma subtypes, including advanced osteosarcoma. We hypothesized that regorafenib would improve progression-free survival (PFS) in patients with sarcoma and report the results of the osteosarcoma cohort. PATIENTS AND METHODS: This trial enrolled patients with progressive metastatic osteosarcoma with measurable disease by RECIST who had received at least one prior line of therapy. Patients were randomly assigned at a ratio of one to one to regorafenib or placebo. Crossover was allowed at time of disease progression. PFS was the primary end point of the study, which was powered to detect a difference of at least 3 months in median PFS. RESULTS: Forty-two patients from 12 centers were enrolled between September 2014 and May 2018. Median age was 37 years (range, 18 to 76 years). Patients had received an average of 2.3 prior therapy regimens. Ten patients receiving placebo crossed over to active drug at time of progression. Study enrollment was stopped early, after a data safety monitoring committee review. Median PFS was significantly improved with regorafenib versus placebo: 3.6 months (95% CI, 2.0 to 7.6 months) versus 1.7 months (95% CI, 1.2 to 1.8 months), respectively (hazard ratio, 0.42; 95% CI, 0.21 to 0.85; P = .017). In the context of the crossover design, there was no statistically significant difference in overall survival. Fourteen (64%) of 22 patients initially randomly assigned to regorafenib experienced grade 3 to 4 events attributed to treatment, including one grade 4 colonic perforation. CONCLUSION: The study met its primary end point, demonstrating activity of regorafenib in patients with progressive metastatic osteosarcoma. No new safety signals were observed. Regorafenib should be considered a treatment option for patients with relapsed metastatic osteosarcoma.
引用
- Davis LE, Bolejack V, Ryan CW, et al. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J Clin Oncol. 2019. PMID: 31013172. doi:10.1200/JCO.18.02374
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。